Log In Get Started
Insider Trading April 13, 2026 07:51 PM

Revolve Co-CEO Sells $413,674 Worth of Stock, Company Announces Strategic Moves

Michael Karanikolas completes share sale and class conversion as Revolve rolls out in-house label and management changes draw analyst attention

By Sofia Navarro RVLV
Revolve Co-CEO Sells $413,674 Worth of Stock, Company Announces Strategic Moves
RVLV

Revolve Group Co-Chief Executive Officer Michael Karanikolas, via MMMK Development, Inc., sold 15,972 shares of Class A Common Stock on April 9, 2026, realizing $413,674 at a weighted average price of $25.90. He also converted an equal number of Class B shares to Class A the same day. The company concurrently disclosed product, analyst rating, and board developments including the launch of REVOLVE Los Angeles, shifts in analyst price targets, and the appointment of Erinn Murphy as director and chair of the Audit Committee.

Key Points

  • Co-Chief Executive Officer Michael Karanikolas, through MMMK Development, Inc., sold 15,972 shares of Class A Common Stock on April 9, 2026 for $413,674 at a weighted average price of $25.90.
  • Karanikolas converted 15,972 shares of Class B Common Stock into Class A Common Stock on the same day.
  • Revolve launched an in-house fashion label, REVOLVE Los Angeles, with items priced from $200 to $3,500 and available on REVOLVE and FWRD; several analysts updated price targets and Stifel reaffirmed a Buy rating following management discussions; Erinn Murphy was appointed director and chair of the Audit Committee.

Insider transaction and share conversion

Revolve Group, Inc. (NASDAQ: RVLV) disclosed that Co-Chief Executive Officer Michael Karanikolas, acting through MMMK Development, Inc., disposed of 15,972 shares of the companys Class A Common Stock on April 9, 2026. The total proceeds from the sale amounted to $413,674. The trades were executed at a weighted average price of $25.90 per share, with individual trade prices spanning from $25.86 to $25.975.

On the same calendar date, Karanikolas completed the conversion of 15,972 shares of Class B Common Stock into an identical number of Class A Common Stock.

Concurrent corporate developments

Revolve Group also announced the debut of its first internal fashion collection, REVOLVE Los Angeles. The line is described as using high-end materials and offering exclusive designs. It will be sold on the companys REVOLVE and FWRD platforms, with items priced between $200 and $3,500.

Market analysts have reacted to Revolves recent performance and strategic plans. Piper Sandler raised its price target for the company to $30, citing strong sales growth and improved margins in the fourth quarter of 2025. TD Cowen adjusted its price target to $28, attributing the change to increased spending that pressures near-term margins, while noting this spending could be a strategic investment for long-term growth. Stifel reiterated a Buy rating and set a $33 price target following conversations with Revolves management about future business drivers.

In a governance update, Revolve Group named Erinn Murphy to its board as a director and appointed her as chairperson of the Audit Committee, citing her extensive financial leadership experience.

Context and takeaways

The insider sale and simultaneous conversion of Class B shares to Class A occurred alongside product, analyst, and board developments that the company described as part of ongoing strategic initiatives. The announcements span product strategy, analyst sentiment adjustments, and a board-level financial oversight addition.

Exact motivations for the insider transaction were not disclosed beyond the mechanics of the sale and conversion.

Risks

  • Increased company spending noted by TD Cowen may pressure near-term margins, presenting short-term profitability risk for the retail and consumer discretionary sectors.
  • Analyst price target adjustments indicate differing views on near-term financial performance, creating uncertainty for investors in the retail and apparel market.
  • The insider sale and class conversion are disclosed without a stated rationale, leaving interpretation of executive intent unclear for shareholders.

More from Insider Trading

OrbiMed Expands Stake in Traws Pharma via Strategic Private Placement Apr 28, 2026 Rexford Industrial Realty General Counsel Completes $1.18 Million Stock Sale Apr 28, 2026 Bicara Therapeutics CMO Executes Rule 10b5-1 Trading Plan Involving Share Sales and Option Exercises Apr 28, 2026 Abbott Laboratories Director Daniel Starks Executes Substantial Open Market Share Purchase Apr 28, 2026 BlackRock President Robert Kapito Executes $9.2 Million Share Sale Apr 28, 2026